#TIDESxAB2025 | BioPharma & Academic

Coming together in an unprecedented event that will provide professionals with a comprehensive look at the most exciting developments in the biopharmaceutical industry, the Antibody & TIDES Summit 2025, will bring together senior leaders, top scientists, and decision-makers across peptide and oligonucleotide therapeutics, antibody engineering, and ADCs, offering a unique opportunity to address the latest challenges and advancements in biologic drug development, across three streams:

• TIDES of Innovation: The Pep & Oligos Summit
• Antibody Engineering: Engineering the Future of Therapeutic Antibodies
• ADC Connect: The Science & Strategy of ADCs

‍

As the biopharmaceutical landscape continues to evolve, peptide and oligonucleotide therapeutics are gaining unprecedented momentum. These complex molecules are at the forefront of the next generation of targeted therapies, offering promising treatments for a variety of diseases, including cancer, cardiovascular conditions, and rare genetic disorders. However, the path from discovery to market for these therapeutics is fraught with unique challenges, particularly in terms of synthesis, scalability, regulatory approval, and commercialisation. TIDES of Innovation will address these challenges through specialised, high-level discussions on optimising synthesis, navigating regulatory landscapes, and developing effective strategies for commercial scale-up. Designed for those at the forefront of this rapidly growing sector, this programme will offer an intimate setting for deep-dive conversations and networking opportunities.

Meanwhile, antibody engineering is revolutionising the treatment of complex diseases, such as cancer and autoimmune disorders. With the European market for monoclonal antibodies poised for significant growth, enhancing manufacturing processes has become more critical than ever. Antibody Engineering will provide a comprehensive platform for exploring the latest advancements in antibody production, including manufacturing optimisation, scale-up challenges, purification techniques, and regulatory compliance. Attendees will also engage in discussions around the integration of single-use technologies, automation, and computational approaches in antibody optimisation.

In addition to these two key programmes, ADC Connect focuses specifically on the rapidly advancing field of Antibody-Drug Conjugates (ADCs), covering critical topics in the design and engineering of ADCs, such as optimising payload-linker technologies and exploring novel ADC payloads to expand therapeutic potential. The agenda will also address the integration of AI and computational tools in ADC development, along with next-generation ADCs and the promise of combination therapies. Regulatory considerations for ADC development, clinical development case studies, and the stability, safety, and pharmacokinetics of ADCs will also be discussed. Manufacturing challenges and supply chain solutions for ADCs will be key themes, ensuring that participants are equipped with the insights needed to overcome the complex challenges in ADC production.

A central feature of the event will be the exhibition and networking sessions, allowing participants to connect with industry leaders, explore new technologies, and form partnerships that will shape the future of biologic therapies. These sessions, combined with expert-led discussions, will offer invaluable insights into the evolving landscape of peptide and oligonucleotide therapeutics, antibody engineering, and ADCs.

By integrating these three focused programmes this event provides a unique, holistic view of the biologics sector. With cutting-edge content, unparalleled networking opportunities, and in-depth discussions on the challenges and innovations across multiple biologic modalities, this summit is essential for anyone looking to stay ahead in the rapidly advancing world of biopharmaceutical development.